An experimental treatment developed by Syntara improved movement in people at high risk of developing Parkinson's disease, ...

As treatment options for Parkinson disease (PD) continue to expand, clinicians increasingly have to consider when patients ...

The drug significantly reduced the amount of time patients spent struggling with the stiffness, slowness and tremors ...

Researchers have carried out the first single-cell analysis of mitochondrial DNA in a population of brainstem neurons that ...

Lundbeck recently announced that its Lu AF28996, an investigational oral prodrug of a D1-like/D2-like dopamine receptor agonist, was associated with increases in good ON-time and ...

For people with Parkinson's disease, higher levels of physical activity were associated with slower declines in thinking and ...

Patients who carry a mutation in the GBA1 gene—the most common genetic risk factor for Parkinson's disease—often experience ...

A new daily pill could help people with Parkinson’s disease live more of their life without symptoms, a trial has found.

The novel GPR6 inhibitor met its primary endpoint in the phase 3 ARISE trial, achieving a statistically significant reduction in daily OFF time and demonstrating non-dopaminergic motor and ...

The Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness.

Arvinas ( ARVN) reported new Phase 1 data for ARV-102, an investigational oral PROTAC degrader designed to target and degrade LRRK2 in patients with Parkinson's disease. The 28-day trial evaluated ARV ...

A 2025 study found that men with a combination of three physical signs "had a 23-fold higher risk of receiving a [Parkinson's ...